Search
Search Results
##search.searchResults.foundPlural##
-
DETECTION OF ANTINUCLEAR ANTIBODIES TARGETING INTRACELLULAR SIGNAL TRANSDUCTION, METABOLISM, APOPTOTIC PROCESSES AND CELL DEATH IN CRITICAL COVID-19 PATIENTS
1375PDF: 1019HTML: 349Suppl. Figure: 184Suppl. Tables: 207 -
Complex and Multifaceted Therapy-Related Myeloid Neoplasm Following Laryngeal Cancer Treated with Cisplatin and Radiotherapy
1198PDF: 767HTML: 1371Figure 1: 194Figure 2: 195 -
UPDATE ON CYTOMEGALOVIRUS INFECTION MANAGEMENT IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS A Consensus Document of the Spanish Group for Hematopoietic Transplantation and Cell Therapy (GETH-TC)
4002Suppl. Files: 1140PDF: 1086Html: 180 -
IMPORTANCE OF CLASSICAL MORPHOLOGY IN THE DIAGNOSIS OF MYELODYSPLASTIC SYNDROME
3363PDF: 2283HTML: 23348Untitled: 208Untitled: 220Untitled: 238 -
ASSESSMENT OF CONGENITAL NEUTROPENIA IN CHILDREN: COMMON CLINICAL SCENERIES AND CLUES FOR MANAGEMENT Assessment of congenital neutropenia in children
2108PDF: 1167HTML: 647 -
Coagulopathy in Patients with Low/Intermediate Risk Acute Promyelocytic Leukemia treated with First Line Arsenic Trioxide in Combination with All Trans Retinoic Acid: A Monocentric Experience. Coagulopathy in APL treated with ATRA and Arsenic Trioxide.
1114PDF: 1084HTML: 452 -
Ponatinib induced improvement of cutaneous lesions associated to accelerated phase of Ph-positive chronic myeloid leukemia
2931PDF: 698HTML: 1938figure 1: 176figure 2: 183 -
TREATMENT OF ADVANCED SYSTEMIC MASTOCYTOSIS WITH MIDOSTAURIN: PRACTICAL GUIDANCE FOR OPTIMAL THERAPY AND MANAGEMENT Advanced systemic mastocytosis and midostaurin
1264PDF: 1015HTML: 224 -
LYON-UNIVERSITY HOSPITAL EXPERIENCE WITH GEMTUZUMAB OZOGAMICIN THERAPY IN ACUTE MYELOID LEUKEMIA: A ‘REAL-LIFE’ STUDY Gemtuzumab ozogamicin in AML
1782PDF: 1180HTML: 253 -
LYMPHOPROLIFERATIVE SYNDROMES ASSOCIATED WITH HUMAN HERPESVIRUS-6A AND HUMAN HERPESVIRUS-6B
3791PDF: 1600HTML: 500Figures . Eliassian: 229 -
THALIDOMIDE AMELIORATES ERYTHROPOIESIS AND IRON HOMEOSTASIS IN TRANSFUSION-DEPENDENT β-THALASSEMIA Thalidomide ameliorates erythropoiesis and iron homeostasis
1422PDF: 1436PDF: 1023HTML: 214 -
-
LENALIDOMIDE IN COMBINATION WITH DEXAMETHASONE IN ELDERLY PATIENTS WITH ADVANCED, RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND RENAL FAILURE
1314PDF: 912HTML: 1281fig 1A: 176figure1B: 152 -
CAR-T CELL THERAPY IN LARGE B CELL LYMPHOMA CAR-T; Large B Cell Lymphoma; Salvage Therapy,
3743PDF: 1468HTML: 188 -
Cardiac toxicity associated with HCV direct antiviral agents Heart in HCV DAAs therapy
1610PDF: 990HTML: 201 -
NOVEL DRUGS IN FOLLICULAR LYMPHOMA
4354PDF: 1521HTML: 1555Untitled: 239 -
LYMPHOCYTES IN PATIENTS WITH CHRONIC ACTIVE EPSTEIN-BARR VIRUS INFECTION EXHIBITED ELEVATED PD-1/PD-L1 EXPRESSION AND A PREVAILING TH2 IMMUNE RESPONSE. EPSTEIN-BARR VIRUS INFECTION EXHIBITED ELEVATED PD-1/PD-L1
2804PDF: 1097HTML: 121 -
The MINI-POLATUZUMAB VEDOTINE PLUS CHP (POLA-R-CHP) VS. MINI-R-CHOP IN PATIENTS OVER 80 YEARS OF AGE WITH DIFFUSE LARGE B-CELL LYMPHOMA: A RETROSPECTIVE, PROPENSITY SCORE-MATCHED ANALYSIS STRATIFIED BY SIMPLIFIED FRAILTY SCORE PolaRCHP vs. RCHOP for older patients
1204PDF: 415HTML: 96 -
CLINICAL AND LABORATORY FEATURES OF SICKLE CELL DISEASE S/D PUNJAB: IMPACT OF HBF AND HYDROXYUREA SCD S/D Punjab
1336PDF: 1151HTML: 122







